Blackrock -NeuroPort Array
Approved for human use in 2004, the NeuroPort Array has been at the core of the most advanced brain-computer interface and intracortical neurophysiology research for nearly two decades.
Approved for Human Use
The FDA-cleared NeuroPort Array has 510(K) clearance for distribution in the U.S.. Other countries such as the EU, Canada, Australia, China, South Korea, and Israel have similar clearances for chronic and subchronic stimulation and recording of human neural activity. Blackrock can assist you through the IRB/IDE approval process.
Safe, Versatile, & Reliable
The NeuroPort Array is designed to be safe, versatile in its utility and stable in its effectiveness for extended periods of time. The durable iridium-oxide electrodes have been proven capable of recording for and stimulating in excess of eight years in a single patient. Since 2004, the NeuroPort has recorded data from human subjects for an aggregate of over 30,000 days with zero reported serious adverse events related to the device.
8 y+
In Humans
1 K+
Peer-Reviewed Citations
30 K+
Days of In-patient Data Collection
510 K
Cleared by the FDA
Supporting the most ambitious BCI Research
The NeuroPort Array is capable of chronic and acute recording and stimulation. It’s been at the center of neuroscience research innovations in neuroprosthetics, implantable brain-computer interfaces, sensory restoration, epilepsy, and learning & memory.